

Resource Summary Report

Generated by [dkNET](#) on Sep 9, 2026

BT-16

RRID:CVCL_M156

Type: Cell Line

Proper Citation

RRID:CVCL_M156

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_M156

Proper Citation: RRID:CVCL_M156

Description: Cell line BT-16 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Atypical teratoid/rhabdoid tumor

Defining Citation: [PMID:17446062](#), [PMID:22206574](#)

Comments: From: Biegel, Jaclyn A.; Children's Hospital of Philadelphia; Philadelphia; USA., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BT-16

Synonyms: BT 16, BT16

Cross References: cancercellines:CVCL_M156, Cell_Model_Passport:SIDM01521, DepMap:ACH-001020, Pharmacodb:BT16_119_2019, Wikidata:Q54798449

ID: CVCL_M156

Record Creation Time: 20220427T215414+0000

Record Last Update: 20260905T174421+0000

Ratings and Alerts

No rating or validation information has been found for BT-16.

No alerts have been found for BT-16.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Altendorf L, et al. (2026) Molecular changes during AT/RT progression associated with epithelial-mesenchymal transition and extracellular matrix changes. *Acta neuropathologica*, 152(1).

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Merk DJ, et al. (2024) Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. *Genome biology*, 25(1), 301.

Drosos Y, et al. (2022) NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. *Molecular cell*, 82(13), 2472.

Graf M, et al. (2022) Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors. *Nature communications*, 13(1), 1544.

Melcher V, et al. (2020) Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance. *Acta neuropathologica*, 139(5), 913.

Oberlick EM, et al. (2019) Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. *Cell reports*, 28(9), 2331.

Wang SZ, et al. (2019) Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 25(19), 5925.